Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Cosette M. Wheeler*, S. Rachel Skinner, M. Rowena Del Rosario-Raymundo, Suzanne M. Garland, Archana Chatterjee, Eduardo Lazcano-Ponce, Jorge Salmeron, Shelly McNeil, Jack T. Stapleton, Celine Bouchard, Mark G. Martens, Deborah M. Money, Swee Chong Quek, Barbara Romanowski, Carlos S. Vallejos, Bram ter Harmsel, Vera Prilepskaya, Kah Leng Fong, Henry Kitchener, Galina MinkinaYong Kuei Timothy Lim, Tanya Stoney, Nahida Chakhtoura, Margaret E. Cruickshank, Alevtina Savicheva, Daniel Pereira da Silva, Murdo Ferguson, Anco C. Molijn, Wim G. V. Quint, Karin Hardt, Dominique Descamps, Pemmaraju V. Suryakiran, Naveen Karkada, Brecht Geeraerts, Gary Dubin, Frank Struyf, VIVIANE Study Group

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

149 Citations (Scopus)
15 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study'. Together they form a unique fingerprint.

Medicine & Life Sciences